Sarcoma Oncology Center
Hospitals & Physicians Clinics · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2811 Wilshire Blvd Ste 414, Santa Monica...Phone Number
(310) 552-9999Website
www.sarcomaoncology.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
2
1
2
1
1
About Sarcoma Oncology Center
Sarcoma Oncology Center, located in Santa Monica, CA, specializes in the treatment of various types of sarcoma, including bone and soft tissue cancers. The center offers a comprehensive range of services, including second opinions, telemedicine, chemotherapy, and access to clinical trials and novel investigational therapies. Their dedicated team of experts focuses on personalized care plans and innovative treatment methodologies to enhance patient outcomes. The center aims to provide hope and support to patients and their families throughout the treatment journey.Explore more
Sarcoma Oncology Center Org Chart
Md
Research Assistant
RP
Administrative Assistant, Billing Collections
IB
Administrative Assistant
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Sarcoma Oncology Center your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Sarcoma Oncology Center launches new products
Funding: Get notified immidiatlly once Sarcoma Oncology Center has new funding data
Check if Sarcoma Oncology Center has recently received funding, and reach out quickly before it becomes old news!
Click to see if Sarcoma Oncology Center had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Sarcoma Oncology Center
Check out if Sarcoma Oncology Center is spiking on competitors!
Earning: See what the market has to say on Sarcoma Oncology Center recently announced quarterly report
Sarcoma Oncology Center, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Sarcoma Oncology Center as Masked Content
Find 3 more new buyers
Compare Similar Companies to Sarcoma Oncology Center
Compare insights from companies similar to Sarcoma Oncology Center, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Sarcoma Oncology Center
<$5M
11-50
Private
-
1989
RA
Ramiro AlvaradoMedical Assistant & Patient Coordinator
Company Profile Activity
Activity Insights
Sarcoma Oncology Center is experiencing very low activity levels compared to other companies in the Hospitals & Physicians Clinics sector.
What does this means?
Sarcoma Oncology Center is drawing exceptional interest within the Hospitals & Physicians Clinics industry, suggesting notable developments or strong market momentum, learn more about Sarcoma Oncology Center.
Sarcoma Oncology Center Tech Stack
A closer look at the technologies used by Sarcoma Oncology Center
Sarcoma Oncology Center News & Media
TYME and The Joseph Ahmed Foundation Announce First Patient Dosed in Phase II (HopES) Trial Evaluating the Potential Benefits of Oral SM-88 for Patients with High-Risk Sarcomas
NEW YORK, Jan. 16, 2020 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced the first sarcoma cancer patient has been dosed at the Sarcoma Oncology Center in the HopES Phase II trial designed to evaluate SM-88 (racemetyrosine) for the treatment of high-risk sarcomas, which are ultra-rare cancers with high unmet medical need. CMBTs are proprietary investigational compounds that are belTyme Provides Clinical and Corporate Update for Fiscal 2Q 2019
NEW YORK, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced a clinical and corporate update for the fiscal quarter ended September 30, 2018. The Company’s lead clinical program, SM-88, is currently being evaluated in ongoing Phase II clinical trials for metastatic pancreatic cancer and biomarker recurrent prostate cancer. During calendar year 2019, the Company is expectedTyme Technologies, Inc. and the Joseph Ahmed Foundation Announce Planned Trial for SM-88 in Ewing’s Sarcoma
NEW YORK, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME) today announced that JAF will provide funding and patient support for an investigator-initiated Phase II trial of SM-88 in patients with previously treated metastatic Ewing’s sarcoma. During our compassionate use program, two third-line refractory metastatic Ewing’s sarcoma patients were treated with SM-88 and, based on available data through February 2018, both achieved complete or partial RECIST responses withCytRx Corporation Highlights NantCell Inc's Aldoxorubicin Clinical Data Presented at the American Society of Clinical Oncology 2018 Annual Meeting
LOS ANGELES, June 7, 2018 /PRNewswire/ -- CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted clinical data from partner NantCell's poster presentation on June 2, 2018 at the American Society of Clinical...
Read more news
Top Hospitals & Physicians Clinics Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Sarcoma Oncology Center
Sign Up For FreeTo access detailed company insights
Sarcoma Oncology Center, located in Santa Monica, CA, specializes in the treatment of various types of sarcoma, including bone and soft tissue cancers. The center offers a comprehensive range of services, including second opinions, telemedicine, chemotherapy, and access to clinical trials and novel investigational therapies. Their dedicated team of... Read More
